#Latest news with #VenturePartners-backedReuters30-01-2025BusinessReutersWeight-loss drug developer Metsera raises $275 million in US IPOJan 30 (Reuters) - Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company said on Thursday. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. Reporting by Prakhar Srivastava and Kanjyik Ghosh in Bengaluru; Editing by Alan Barona
Reuters30-01-2025BusinessReutersWeight-loss drug developer Metsera raises $275 million in US IPOJan 30 (Reuters) - Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company said on Thursday. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. Reporting by Prakhar Srivastava and Kanjyik Ghosh in Bengaluru; Editing by Alan Barona
30-01-2025
